Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 15/20 | 0.68 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26416614 | 0.92 | PTGER4 (0.57) | PTGER4PTGER2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL881393 | 0.91 | PTGER4 (0.72) | PTGER4PTGER2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL26418537 | 0.90 | PTGER4 (0.74) | PTGER4PTGER2PHGDH | |
| SCHEMBL28686062 | 0.90 | PTGER4 (0.74) | PTGER4PTGER2PHGDH | |
| SCHEMBL881184 | 0.86 | PTGER4 (0.70) | PTGER4PTGER2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24861863 | 0.85 | PTGER4 (0.74) | PTGER4PTGER2PHGDH | |
| SCHEMBL28690240 | 0.85 | PTGER4 (0.74) | PTGER4PTGER2PHGDH | |
| SCHEMBL881397 | 0.85 | PTGER4 (0.79) | PTGER4PTGER2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15249912 | 0.84 | PTGER4 (0.67) | PTGER4PTGER2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL881499 | 0.84 | PTGER4 (0.69) | PTGER4PTGER2PHGDHKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | PTGER4 1/4885PTGER2 3/4885CYP1A2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.